FORA Capital’s Core Laboratories CLB Stock Holding History

FORA Capital’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,226	Closed	-$200K	–	459
2022 Q1	$200K	Buy	+6,226	New	+$175K	0.04%	489
2021 Q3	–	Sell	-4,981	Closed	-$194K	–	453
2021 Q2	$194K	Buy	+4,981	New	+$179K	0.04%	447
2020 Q2	–	Sell	-11,867	Closed	-$123K	–	950
2020 Q1	$123K	Buy	+11,867	New	+$332K	0.03%	561

Other funds holding CLB

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FORA Capital's CLB Position: Q2 2022 in Review

FORA Capital sold out of Core Laboratories (CLB) in Q2 2022, closing a stake of 6,226 shares — an estimated $200K sold.

FORA Capital first reported a position in CLB in Q1 2020 and held it in 3 quarters. The position peaked at $200K in Q1 2022. 176 funds tracked by Wall St. Rank hold CLB as of Q2 2022.

FORA Capital reported no remaining Core Laboratories position as of Q2 2022 after selling out during the quarter.
FORA Capital sold 6,226 Core Laboratories shares in Q2 2022, an estimated $200K.
FORA Capital first reported a position in Core Laboratories in Q1 2020 and held it in 3 quarters.
FORA Capital's Core Laboratories position peaked at $200K in Q1 2022.
176 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2022.

Based on FORA Capital's 13F filing for Q2 2022, filed 11 Aug 2022.